Ion channel modulators

Vaccine research
#Autoimmune disease #Ion channel modulators #Phase I trial #Zealand Pharma

Ion channel blocker for autoimmune disease well tolerated in trial

Zealand Pharma has shared positive Phase I multiple ascending dose (MAD) topline results for the company’s novel Kv1.3 ion channel blocker, ZP9830.  The MAD part of the first-in-human, single-centre, randomised, double-blind, placebo-controlled Phase I trial was designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple… Read More

#News

Ion channel modulators
#CNS #Drug discovery #Ion channel modulators #Therapeutic targets #Webinar

Last chance: Discover opportunities in ion channel drug discovery

Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, will provide data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the… Read More

Webinar date:
Supported by Axxam
#News

Ion channel modulators
#CNS #Drug discovery #Ion channel modulators #Therapeutic targets #Webinar

Discover why ion channels don’t have to be difficult drug discovery targets

Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, will provide data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the… Read More

Webinar date:
Supported by Axxam
#News

Ion channel modulators
#CNS #Drug discovery #Ion channel modulators #Therapeutic targets #Webinar

Register now: Understand current and future ion channel targets

Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, will provide data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the… Read More

Webinar date:
Supported by Axxam
#News

Ion channel modulators
#CNS #Drug discovery #Ion channel modulators #Therapeutic targets #Webinar

Webinar: Current trends in ion channel drug discovery

Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, will provide data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the… Read More

Webinar date:
Supported by Axxam
#News

Ion channel modulators
#CNS #Drug discovery #Ion channel modulators #Therapeutic targets

Ion channel drug discovery – current trends and future opportunities

Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, provides data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the last… Read More

Webinar date:
Supported by Axxam
#Webinars